Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-08-22 00:00:00 ET · period of report 2024-08-20 · accession 0001714899-24-000197 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-22 | 2024-08-20 | DNLI | Watts Ryan J. | Pres, CEO, Dir | S - Sale | $23.79 | -2,260 | 235.8K | -0.9% | -$53.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-20 | S | D | 2,260 | $23.79 | 235,807 | D | — | — | (F2) Includes 197,200 Unvested RSUs. |